Treatment of pulmonary arterial hypertension (PAH) with oral endothelin-receptor antagonist bosentan in systemic sclerosis: BREATHE-1 trial and clinical experience

被引：0
|
作者：
Ahmadi-Simab, K
Lamprecht, P
Hellmisch, B
Gross, WL
机构：
[1] Univ Klinikum Schleswig Holstein, Poliklin Rheumatol, D-23538 Lubeck, Germany
[2] Rheumaklin Bad Bramstedt, D-23538 Lubeck, Germany
来源：
ZEITSCHRIFT FUR RHEUMATOLOGIE | 2004年 / 63卷 / 06期
关键词：
D O I：
10.1007/s00393-004-0594-3
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：495 / 497
页数：3
相关论文
共 50 条
  • [41] Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan
    Barst, Robyn J.
    Langleben, David
    Badesch, David
    Frost, Adaani
    Lawrence, E. Clinton
    Shapiro, Shelley
    Naeije, Robert
    Galie, Nazzareno
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 47 (10) : 2049 - 2056
  • [42] Improvement of markers endothelial damage in patients with pulmonary arterial hypertension (PAH) related to systemic sclerosis (SSC) after bosentan treatment.
    Del Papa, N
    Cortiana, M
    Comina, D
    Maglione, W
    Silvestris, I
    Manara, M
    Maresta, A
    Cortelezzi, A
    ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : S164 - S164
  • [43] First clinical experience with endothelin receptor antagonist bosentan used in patients with pulmonary hypertension: results of a one-year study
    Avdeev, S. N.
    Tsareva, N. A.
    Neklyudova, G. V.
    Chuchalin, A. G.
    TERAPEVTICHESKII ARKHIV, 2013, 85 (03) : 38 - +
  • [44] Bosentan for the treatment of systemic sclerosis-associated pulmonary arterial hypertension, pulmonary fibrosis and digital ulcers
    Jain, Manu
    Varga, John
    EXPERT OPINION ON PHARMACOTHERAPY, 2006, 7 (11) : 1487 - 1501
  • [45] Efficacy and safety of chronic treatment with the oral selective endothelin-A receptor blocker Sitaxsentan in pulmonary arterial hypertension (PAH)
    Barst, RJ
    Rich, S
    Horn, EM
    McLaughlin, VV
    Kerstein, D
    Widlitz, AC
    McFarlin, JD
    Dixon, RAF
    CIRCULATION, 2000, 102 (18) : 427 - 427
  • [46] BOSENTAN AN ORAL NONSELECTIVE ENDOTHELIN (ET) RECEPTOR ANTAGONIST, BLUNTS MONOCROTALINE-INDUCED PULMONARY-HYPERTENSION
    HILL, NS
    WARBURTON, RR
    PIETRAS, LA
    KLINGER, JR
    FASEB JOURNAL, 1995, 9 (03): : A600 - A600
  • [47] Successful treatment of systemic sclerosis-related digital ulcers and sarcoidosis with endothelin receptor antagonist (bosentan) therapy
    Tillon, J
    Hervé, F
    Chevallier, D
    Muir, JF
    Levesque, H
    Marie, I
    BRITISH JOURNAL OF DERMATOLOGY, 2006, 154 (05) : 1000 - 1002
  • [48] Macitentan, a tissue-targeting endothelin receptor antagonist for the potential oral treatment of pulmonary arterial hypertension and idiopathic pulmonary fibrosis
    Raja, Shahzad G.
    CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2010, 11 (09) : 1066 - 1073
  • [49] Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension - A 1-year follow-up study
    Sitbon, O
    Basesch, DB
    Channick, RN
    Frost, A
    Robbins, IM
    Simonneau, G
    Tapson, VF
    Rubin, LJ
    CHEST, 2003, 124 (01) : 247 - 254
  • [50] Effects of the endothelin receptor antagonist bosentan on hemodynamics and exercise capacity in Japanese patients with mildly symptomatic pulmonary arterial hypertension
    Hatano, Masaru
    Yamada, Hidehiro
    Fukuda, Keiichi
    Yoshioka, Koichiro
    Funauchi, Masanori
    Kuwana, Masataka
    Sata, Masataka
    Taniguchi, Mitsugu
    Nakanishi, Norifumi
    Saito, Takefumi
    Saji, Tsutomu
    Sasayama, Shigetake
    HEART AND VESSELS, 2015, 30 (06) : 798 - 804
12345